乳腺微血管重建住院时间全国趋势:基于美国外科医师学会国家外科质量改进计划数据库的10,465例评估
该研究利用2012至2018年美国外科医师学会国家外科质量改进计划数据库,纳入10,465例接受微血管乳腺重建的女性患者,分析住院时间、并发症及再入院率的变化趋势。结果显示住院时间从4.47天显著降至3.90天(p<0.01),而轻微及主要并发症率保持稳定,主要并发症呈下降趋势(从27%降至21%,p=0.07),30天再入院率、手术部位感染和伤口裂开率保持稳定,输血或出血率下降(p=0.02)。作者认为缩短住院时间的努力在未增加并发症或再入院率的情况下取得成功。
要点
- 2012至2018年微血管乳腺重建住院时间从4.47天降至3.90天(p<0.01)。
- 主要并发症率呈下降趋势(从27%降至21%,p=0.07),轻微并发症率保持稳定。
- 30天再入院率、手术部位感染和伤口裂开率保持稳定,输血或出血率下降(p=0.02)。
核心结论
- 基于2012至2018年全国样本,微血管乳腺重建患者住院时间显著缩短,且未伴随并发症和再入院率增加。
- 当前缩短住院时间的努力在未增加并发症或再入院率的情况下取得成功。
研究设计与样本
- 回顾性数据库研究,使用2012至2018年美国外科医师学会国家外科质量改进计划数据库。
- 纳入10,465例接受微血管乳腺重建(CPT 19364)的女性患者。
- 采用多变量逻辑回归模型和Mann-Kendall趋势检验评估住院时间与并发症及再入院率之间的关联。
主要发现
- 2012至2018年间,自体微血管乳腺重建手术数量逐年增加。
- 住院时间从2012年的4.47天显著降至2018年的3.90天(p<0.01)。
- 轻微和主要并发症率保持稳定,主要并发症呈下降趋势(从27%降至21%,p=0.07)。
- 30天再入院率、手术部位感染和伤口裂开率在研究期间保持稳定。
- 输血或出血率下降(p=0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Decreasing length of stay benefits patients and hospital systems alike. This should be accomplished safely without negatively impacting patient outcomes. The authors hypothesize that in the United States, the average length of stay for patients undergoing microsurgical breast reconstruction has decreased since 2012 without a concurrent increase in complication and readmission rates. METHODS: The authors identified female patients who underwent microvascular breast reconstruction (CPT 19364) from the 2012 to 2018 National Surgical Quality Improvement Program database. Trends in complication and readmission rates and length of stay were examined over 7 years. Multivariable logistic regression models and Mann-Kendall trend tests were used to evaluate associations between length of stay and complication and readmission rates. RESULTS: A total of 10,465 cases were identified. The number of autologous microvascular breast reconstruction procedures performed increased annually between 2012 and 2018. Length of stay decreased significantly from 2012 to 2018 (from 4.47 days to 3.90 days) (p < 0.01). Minor and major complication rates remained constant, although major complications showed a decreasing trend (from 27 percent to 21 percent) (p = 0.07). Thirty-day readmission, surgical-site infection, and wound dehiscence rates remained consistent over the study period, whereas rates of blood transfusion or bleeding decreased (p = 0.02). CONCLUSIONS: Using a national sample from 2012 to 2018, the authors observed a significant decrease in length of stay for patients undergoing microvascular breast reconstruction without a concurrent increase in complication and readmission rates. Current efforts to reduce length of stay have been successful without increasing complication or readmission rates. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.
引用
- Holoyda KA, Magno-Padron DA, Carter GC, et al. National Trends in Length of Stay for Microvascular Breast Reconstruction: An Evaluation of 10,465 Cases Using the American College of Surgeons National Surgical Quality Improvement Program Database. Plast Reconstr Surg. 2022. PMID: 34898525. doi:10.1097/PRS.0000000000008706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。